| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/05/2024 | 12:30 | Business Wire | Sage Therapeutics to Participate in Upcoming May Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 25/04/2024 | 12:30 | Business Wire | Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress | NASDAQ:SAGE | Sage Therapeutics Inc |
| 17/04/2024 | 12:30 | Business Wire | Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease | NASDAQ:SAGE | Sage Therapeutics Inc |
| 11/04/2024 | 12:30 | Business Wire | Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 28/02/2024 | 12:30 | Business Wire | Sage Therapeutics to Present at Upcoming March Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 21/02/2024 | 22:35 | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 15/02/2024 | 23:02 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SAGE | Sage Therapeutics Inc |
| 14/02/2024 | 13:49 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SAGE | Sage Therapeutics Inc |
| 14/02/2024 | 13:20 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 14/02/2024 | 12:45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SAGE | Sage Therapeutics Inc |
| 14/02/2024 | 12:30 | Business Wire | Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress | NASDAQ:SAGE | Sage Therapeutics Inc |
| 31/01/2024 | 12:30 | Business Wire | Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 23/01/2024 | 14:13 | Edgar (US Regulatory) | Form SC TO-I - Tender offer statement by Issuer | NASDAQ:SAGE | Sage Therapeutics Inc |
| 08/01/2024 | 12:32 | Business Wire | Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:SAGE | Sage Therapeutics Inc |
| 08/01/2024 | 12:30 | Business Wire | Sage Therapeutics Announces Changes to Board of Directors | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/01/2024 | 12:30 | Business Wire | Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 19/12/2023 | 14:32 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:SAGE | Sage Therapeutics Inc |
| 19/12/2023 | 14:30 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SAGE | Sage Therapeutics Inc |
| 14/12/2023 | 12:30 | GlobeNewswire Inc. | ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. | NASDAQ:SAGE | Sage Therapeutics Inc |
| 08/12/2023 | 15:00 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:SAGE | Sage Therapeutics Inc |
| 08/12/2023 | 14:30 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:SAGE | Sage Therapeutics Inc |
| 08/11/2023 | 12:30 | Business Wire | Sage Therapeutics to Present at Upcoming November Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 07/11/2023 | 13:29 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 07/11/2023 | 13:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 07/11/2023 | 12:30 | Business Wire | Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress | NASDAQ:SAGE | Sage Therapeutics Inc |
| 24/10/2023 | 12:30 | Business Wire | Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 18/10/2023 | 13:10 | Dow Jones News | Sage Therapeutics Gets FDA Orphan Designation for SAGE-718 in Huntington's | NASDAQ:SAGE | Sage Therapeutics Inc |
| 18/10/2023 | 12:30 | Business Wire | Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease | NASDAQ:SAGE | Sage Therapeutics Inc |
| 06/09/2023 | 12:30 | Business Wire | Sage Therapeutics to Present at Upcoming September Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 31/08/2023 | 12:30 | Business Wire | Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement | NASDAQ:SAGE | Sage Therapeutics Inc |